The IMPACT study evaluates targeted PCa screening for men carrying genetic alterations in BRCA1, BRCA2, and Lynch syndrome genes (MSH2, MSH6, and MLH1), aiming to detect clinically significant PCa (csPCa) using a PSA threshold of 3.0 ng/ml.10, 11. This evidence concerns the gene MSH2 and posterior cortical atrophy.